Abstract
circulating strain diversity and incorporate the within-host diversity of HIV. To address this, we 23 identified a set of gRNAs targeting HIV LTR, gag and pol using publicly available sequences for 24 these genes. We ranked gRNAs according to global conservation across HIV-1 group M and 25 within subtypes A-C. By considering paired and triplet combinations of gRNAs, we found triplet 26 sets of target sites such that at least one of the gRNAs in the set was present in over 98% of all 27 globally-available sequences. We then selected 59 gRNAs from our list of highly-conserved LTR 28 target sites and evaluated in vitro activity using a loss-of-function LTR-GFP fusion reporter. We 29 achieved efficient GFP knockdown with multiple gRNAs and found clustering of highly active 30 gRNA target sites near the middle of the LTR. Using published deep-sequence data from HIV-31 infected patients, we found that globally conserved sites also had greater within-host target 32 conservation. Lastly, we developed a mathematical model based on varying distributions of 33 within-host HIV sequence diversity and enzyme efficacy. We used the model to estimate the 34 number of doses required to deplete the latent reservoir and achieve functional cure thresholds. 35
Our modeling results highlight the importance of within-host target site conservation. While 36 increased doses may overcome low target cleavage efficiency, inadequate targeting of rare 37 strains is predicted to lead to rebound upon ART cessation even with many doses. 38 39 40 Author summary 41 The field of genome engineering has exploded over the last decade with the discovery of 42 targeted endonucleases such as CRISPR/Cas9. Endonucleases are now being used to develop 43 a wide range of therapeutics and their use has expanded into antiviral therapy against latent 44 viral infections like HIV. The idea is to induce mutations in latent viral genomes that will render 45 them replication-incompetent, thereby producing a functional cure. Although a great deal of 46 progress has been made, most studies to date have relied on molecular clones that represent 47 "ideal" targets. For clinical success and broad applicability, these therapies need to account for 48 viral genetic diversity within and between individuals. Our paper examines the impact of HIV 49 diversity on CRISPR-based cure strategies to determine the predictors of future clinical 50 success. We performed an exhaustive and detailed computational analysis to identify optimal 51
Introduction

58
Despite the success of combination antiretroviral therapy (cART) in suppressing HIV viremia, 59 reservoirs of latently-infected cells remain the major barrier for HIV cure [1] . The HIV latent 60 reservoir is composed of long-lived infected cells harboring replication-competent proviruses 61 with limited transcription that can reactivate and reseed the reservoir upon cART interruption 62 [2, 3] . A promising therapeutic strategy for achieving cure involves depleting the reservoir by 63 direct disruption of proviral genomes using engineered DNA-editing enzymes such as 64 CRISPR/Cas9 nucleases. A growing body of research shows that endonuclease-induced 65 mutation of essential viral genes or excision of provirus can render the virus unable to replicate 66 [4] [5] [6] [7] [8] [9] [10] [11] [12] . If performed on a large scale, this approach could yield pharmacologically significant 67 reservoir reduction. However, viral reservoirs are highly diverse, even in well-suppressed 68 individuals [13, 14] , and this diversity remains a major challenge for the application of genome 69 editing strategies towards an HIV cure. Effective targeting of all viral genetic variants within an 70 infected individual will be crucial for achieving sufficient reservoir reduction to prevent viral 71 rebound upon cART cessation [15, 16] and preventing the emergence of resistance to this 72 therapy [11] . 73
Thus far, studies used to demonstrate the viability of gene editing strategies against HIV 74 have primarily targeted single molecular clones that provide ideal endonuclease target site 75 recognition [7, 8] . Multiple classes of gene-editing enzymes have been studied, but the 76 CRISPR/Cas9 system has gained popularity in recent years due to its effectiveness, relative 77 simplicity, and ease of use. Several computational tools now exist to identify CRISPR target 78 sites, to predict the activity of guide RNAs (gRNAs) targeting those sites, and to identify and 79 score gRNAs based on multiple factors including predicted off-target activity [17] [18] [19] . However, 80 no available tools allow guide selection based on predicted target site conservation or predicted 81 clinical efficacy based on viral diversity. The identification and characterization of the most 82 conserved target sites on a group-or subtype-specific basis will allow rapid selection of gRNAs 83 when deep sequencing of a patient's reservoir is not practical or feasible. Furthermore, because 84 the virus can evolve resistance to endonuclease targeting [11] , multiple sites may need to be 85 targeted concurrently in order to prevent the emergence of resistance. Therefore, the selection 86 of multiplexed sets of gRNAs must account for the diversity of circulating strains across a wide 87 range of infected people, and dosing strategies must consider within-host diversity of HIV to 88 maximize the probability of a functional cure. 89
Here we present a CRISPR gRNA design strategy that selects target sites not only by 90 predicted efficacy and specificity but also by prevalence in the population. We first created a 91 database of highly conserved target sites in HIV LTR, gag, and pol focusing on group-and 92 subtype-level conservation using information about the global sequence diversity of HIV. We 93 used this database to identify highly-conserved target site pairs and triplets to create multiplex 94 gRNA designs predicted to maximize targeting and reduce the probability of treatment 95 resistance. From this analysis, we identified and tested 59 LTR guides using a fluorescent 96 reporter to quantify activity in vitro. We then used deep-sequence data from HIV-infected 97 individuals to determine target site conservation and probability of cleavage by individual gRNAs 98 in our list. Finally, we used a mathematical model to predict the number of doses that would be 99 required to achieve functional cure thresholds, while accounting for varying levels of target site 100 diversity and enzyme efficacy. 101
102
Results
103
Broadly-targeting spCas9 gRNAs against HIV gag, pol, and LTR We determined predicted on-target cleavage efficiency and off-target activity for each 132 guide sequence (Fig 2) using the sgRNA designer tool [17] . Predicted on-target activity scores 133 were in the range [0,1] where a score of 1 was associated with successful knockout in the 134 experiments of Doench et al. [17, 24] and gRNAs with scores < 0.2 were generally excluded 135 because they were shown to be predictive of poor activity. Mean predicted activity scores 136 across all identified guides were 0.50 (SD 0.12, n = 246) for LTR, 0.49 (SD 0.13, n = 573) for 137 gag and 0.47 (SD 0.13, n = 897) for pol. From the list of gRNAs identified, we excluded 10 from 138 gag and 26 from pol from further analyses due to high predicted off-target activity scores. No 139 significant correlation was observed between predicted activity and target site conservation 140 (Table S1A) 
Multiplexed gRNA designs
151
For each gene, we determined the number of sequences that could be targeted by pairs and 152 triplets of gRNAs in group M overall, and in each subtype A-C. We determined that just 2 153 strategically selected gRNAs are sufficient for targeting 100% of LTR and pol sequences in the 154 current global alignment for Subtype A, and 3 gRNAs are able to target over 98% of all 155 sequences in Subtypes A-C. However, when considering all group M sequences, the maximum 156 percentage of sequences targeted by triplet sets of gRNAs drops to 88.8% for LTR, 95.5% for 157 gag and 99.2% for pol (Table 1) . Overall, better coverage of group M, or subtypes A-C 158 sequences was achieved when pair or triplet gRNAs targeted pol suggesting that pol is an ideal 159 therapeutic target for targeted mutagenesis with multiplexed guide RNAs. The two most 160 conserved LTR sites in the whole of group M (rank 1 and 2) were also the most prevalent target 161 sites in the individual subtypes, but this was not the case for gag and pol (Table S2) . 162
163
Functional testing of selected gRNAs
164
From our list of 246 gRNAs targeting LTR, we identified 59 gRNAs for functional testing by first 165 considering the most conserved target sites in group M and each subtype. We then included 166 any gRNAs that increase the number of sequences targeted when combined in pairs or triplets 167 with the previous list ( Fig S1A) . In order to test the activity of these guides in vitro, we designed 168 LTR-GFP fusion reporter constructs using consensus sequences for group M and subtypes A-C 169 ( Fig 3A, Fig S1B) . We tested the ability of each gRNA to knock down reporter GFP expression 170 in HEK293 cells following co-transfection with a plasmid expressing spCas9 mCherry containing We compared measured gRNA activity to predicted activity scores from the sgRNA 186 designer ( Fig 3B) ; there was a trend towards weak positive correlation between predicted and 187 measured activity (Pearson's r = 0.25, n = 59, 95% CI = 0.00-0.48, Table S1B ). We observed a 188 reduction of GFP fluorescence intensity with 52 out of 59 gRNAs ( Fig patients. We started with our list of all pol target sites that we identified above from group and 205 subtype consensus sequences from 2016 LANL alignments, labelling each target site according 206 to the consensus sequence it was identified from (300, 317, 304 and 328 target sites from group 207 M and subtype A-C consensus sequences respectively, 1249 sites total, 897 unique sites). 208
From this combined list of globally conserved target sites, we determined whether each site was 209 present in each patient's HIV consensus sequence (Tables S4 and S5 ) [25] . Across infected 210 persons, an average of 89.4 group M target sites (i.e. 29.80% of all group M sites identified) and 211 119.9 subtype B sites (39.44% of all subtype B target sites identified) were found to be also 212 present within patient consensus sequences (SD 11.14 sites/3.24% and 9.84 sites/3.71% 213 respectively, n = 10 patients), while subtype A and C sites were identified less frequently (Fig  214   4A ). Since subtype B is highly prevalent in Brazil this was not surprising. Five target sites were 215
found to be present in all 10 patient consensus sequences (Table S5 ) and one of these 216 (GATGGCAGGTGATGATTGTGTGG) was also highly conserved in the global alignment for 217 subtype B (present in 87.09% of LANL sequences). These five target sites were found to occur 218 between positions 2294 and 2981 in pol. In addition, we identified gRNA target sites directly 219 from the patient's consensus sequence. The number of directly identified sites for each patient 220 ranged between 276 and 313 (mean = 299.30, SD = 10.83, n = 10). Out of 1712 unique sites 221 generated from the 10 patients' consensus sequences, 351 were present in our list of globally 222 conserved sites. Of the remaining sites, 1135 were only present in a single individual and 87 223 sites were found in more than 5 individuals. With one exception 224 (GTTTCTTGCCCTGTCTCTGCTGG), every site that was present in more than 5 individuals 225 was also present in our global list. 226 Within-host target site conservation for each identified target site using deep-sequence data for 230 4 patients, summarized using box plots. Black dots indicate outlier target sites (outside 1.5xIQR) 231 and target sites are grouped and colored according to which consensus sequence they were 232 identified from (the group-or subtype-level consensus from LANL alignments, or from the 233 patient's HIV consensus sequence). 234
235
Next we used deep-sequence data from each of these individuals [25] to determine the 236 degree of conservation of each target site within the patient's virus quasispecies population. In 237 order to accurately quantify rare target site variants, we identified 4 out of 10 patient datasets 238 where mean coverage across all identified target sites was above 5000x (Table S2 , Fig S2B) . 239
For each of these patients, we determined within-host target site conservation by computing the 240 percentage of reads in the alignment containing an exact match to the site. Within-host target 241 site conservation was found to vary dramatically for individual gRNAs and between individual 242 patients, ranging between 5.5% and 95.6% with a mean of 83.5% (SD 14.3%, n = 2298) (Fig  243   4B) . 244
Within-host target site conservation was an average of 3.4% higher for sites identified 245 from our global list (range of means = 84.7% -86.5%, n = 4 patients) compared to sites that 246 were only present in the patient's sequence (mean = 81.6%, n = 4, p = 0.026) but the difference 247 between groups was not statistically significant (F-test, p = 0.15). Target sites identified from 248 group M or subtype B consensus sequences tended to be more conserved than sites identified 249 from the patient sequence, but the differences were not statistically significant (both 3. unevenly abundant, and are assumed to follow a log-normal distribution so that each 260 quasispecies contains 1-1,000 members. Further, each quasispecies decays in size with a rate 261 drawn from the distribution of reservoir decay rates (half-life 3-4 years) described previously 262 [26, 27] . In the absence of CRISPR therapy, the model simulates a fluctuating but, on average, 263 slowly decaying HIV reservoir with varying compositions [28] . The parameters analyzed were 264 enzyme efficacy (߳, the probability of successful mutagenic DNA cleavage at the target site) andcoverage proportion (ߩ, the proportion of sequences that would respond to enzyme). The 266 measure of target site conservation is based on our analysis of patient samples. 267
Including CRISPR, our simulations suggest that treatments with gRNAs targeting a 268 single site will be insufficient to achieve functional cure even at high levels of target site 269 conservation (99%) and enzyme efficiency (0.99) (Fig 5A, Fig S3) . Enzyme efficacy is relatively 270 unimportant in this case, only affecting the number of treatments needed to remove the 271 sensitive quasispecies. Once removed, additional treatments provide no additional benefit 272 because insensitive quasispecies dominate the reservoir (Fig 5B) . However, if it is possible to 273 achieve 100% coverage of all quasispecies through the selection of a multiplexed set of gRNAs 274 that can be delivered simultaneously, the number of treatments to deplete the reservoir to the 275 first cure threshold (100-fold decrease [16] ) can be achieved in 1-5 treatments depending on 276 efficacy (Fig 5C) , whereas the second threshold ( 
Discussion
298
Gene editing using CRISPR/Cas9 has the potential to effect a functional cure for HIV through 299 targeted mutagenesis or proviral genome excision [29] . This approach has now been 300 demonstrated in multiple proof-of-concept in vitro and in vivo studies [7, [9] [10] [11] 20, [30] [31] [32] . While 301 laboratory demonstration of gRNA activity has largely relied on clonal populations of lab-302 adapted HIV strains, clinical applications of this method will need to consider the wide intra-and 303 inter-host diversity of HIV. The global diversity of HIV-1 is reflected in the classification of 304 viruses into four broad groups (M, N, O, and P) that are 25-40% divergent, and within-group 305 subtypes that are up to 15% divergent [23] . This remarkable global diversity of HIV is the result 306 of within-host evolution and adaption to immune pressure, and transmission of genetic variants 307 from the host quasispecies over multiple rounds of viral replication. Target sites chosen for gene 308 editing will therefore also need to reflect this genetic variability within and between individuals. 309
Globally conserved target sites are good starting points for gRNA design; if their high 310 frequencies in the population are the result of selection, endonuclease-induced mutations are 311 more likely to be highly deleterious to the virus. Indeed, it has been shown that highly conservedtarget sites are associated with improved antiviral activity, and importantly, delayed viral escape 313 [10, 31] . Identification of sites that are conserved at a global or subtype level may also allow for 314 future deployment of these therapies in situations where obtaining individual patient HIV 315 sequence data may not be feasible or practical. To this end, we identified gRNA target sites in 316 HIV LTR that were highly conserved in global consensus sequences and tested the activity of 317 these guides in vitro. Using a separate set of deep-sequence data [25], we showed that sites 318 identified from our list of globally conserved targets that were present in the patient's sequence 319 also showed greater within-host conservation. 320
Gene therapy approaches designed to cure an infected individual will need to ensure 321 that all relevant within-host variants are targeted. Although early initiation of long-term cART has 322 been shown to reduce the rate of HIV evolution, the virus is still thought to accumulate about 323 0.97 mutations/kb/year [13, 14] . Using a mathematical model, we showed that variants that are 324 not recognized and cleaved will be the major barrier to achieving functional cure thresholds. 325
These variants, if replication-competent, have the potential to reactivate upon cART interruption 326 and reseed the reservoir. Our model makes an assumption about the underlying distribution of 327 quasispecies abundance, which is not fully understood, but notably, three disparate 328 assumptions all resulted in similar conclusions. Estimating time to rebound based on reservoir 329 reduction is challenging and various estimates of thresholds for depletion exist [15, 16, 33, 34] . In 330 our simulations, we have included estimates for median 1 y and median lifetime remission from 331 HIV rebound. However, the depletion itself depends on targeting viral quasispecies diversity, 332 which is not yet fully understood. 333
The efficiency of gene delivery to target cells is another key factor determining 334 therapeutic outcome. We have also not explicitly incorporated gene delivery in the current 335 model but instead assumed that it is captured within the cleavage efficiency parameter HIV has also been shown to rapidly escape endonuclease targeting [10, 11, 31] , 341
suggesting that therapies will need to target multiple sites concurrently in order to achieve 342 sustained rebound and prevent the emergence of treatment resistance. Our simulations support 343 these findings and show that even enzymes with high on-target efficiency will fail to produce a 344 functional cure if there are target site variants present at frequencies as low as 1%. Two recent 345 proof-of-principle studies showed that an approach with dual gRNAs targeting multiple genes 346 can delay or completely prevent viral escape [30, 36] . We identified paired and triplet sets of 347 gRNA target sites that occur in over 98% of the population. Since these sites are likely to also 348 be highly conserved within-host (as our results suggest), they would be good candidates for 349 testing in vitro for activity. Although our mathematical model takes multiplexed gRNAs into 350 consideration within the parameter ߩ , it does not explicitly include dynamic emergence of 351 treatment-resistant variants. Our model framework is amenable to emergent resistance, but was 352 not included for lack of information on these dynamics. In addition, although many recent 353 studies have targeted LTR, we have shown that pol is a better genomic target for directed 354 mutagenesis due to target site conservation. As a result, we believe that targeting multiple sites 355 within pol may be a better approach than targeting LTR alone, which generally contains less-356 conserved sites. 357
One of the limitations of our within-host analysis is that we do not have detailed 358 information about the patient cohort [25] such as treatment status, age at HIV diagnosis and 359 time of cART initiation and interruption, if any. These factors could potentially impact reservoir 360 diversity. However, the current analysis is primarily aimed at demonstrating the importance and 361 feasibility of designing gRNAs targeting a diverse viral population. Future work needs to address 362 this in greater detail, possibly incorporating treatment-related variables to select gRNA designs. 363
364
Materials and methods
365
HIV sequence datasets and pre-processing Genbank. These pre-processing steps ( Fig S2) were performed within the Galaxy software 376 framework (https://galaxyproject.org/). 377 378 gRNA target site analysis 379 We developed a custom script to identify gRNA target sites for an input sequence given a 380 specified PAM sequence (default 'NGG' for spCas9) and desired gRNA length w (default 20 nt). 381
The algorithm finds all matches to the PAM sequence in the forward and reverse directions and 382 returns, for each match, w bases upstream of the PAM sequence. We then used the sgRNAdesigner from the Broad Institute (https://portals.broadinstitute.org/gpp/public/analysis-384 tools/sgrna-design) to determine predicted on-target efficacy score and off-target scores (threat 385 sequence for each patient using the script described above, excluding any sites containing 453 degenerate bases. We also determined which of the target sites we had previously identified 454 from group-and subtype-level consensus sequences for pol were present in the patient 455 consensus sequence. Using the average number of reads overlapping all identified target sites, 456
we excluded any patients with <5000x target site depth since we were interested in variants that 457 may escape targeting by candidate gRNAs. For each target site, we determined the number of 458 reads in the alignment containing an exact match to the target site and excluded any sites 459 where coverage was less than 5000x. We then used the total number of reads that completely 460 overlap the target site to calculate the percentage of exact target site matches. 461
462
Statistical analysis of within-host conservation
463
To test whether there were differences in target site conservation measured by mean 464 percentages of exact target site matches per total reads, a linear mixed model was fit with 465 percentage as the outcome and the consensus sequence group (group M, subtypes A-C, and 466 patient) as the predictors. A random intercept for each subject by consensus group was used to 467 account for within subject and group variation across the repeated outcomes. An overall test 468 was performed from ANOVA for mixed models using the lmerTest package in R [44] . Post-hoc 469 pairwise tests were also performed comparing the patient-derived sequences, group M, and 470 subtype B (the circulating strain in the patient population). To compare the conservation using 471 patient target sites to the consensus groups, we pooled group M and subtypes A-C into a single 472 group for comparison in the model, while the random effects specification remained the same. 473 P-values corrected for multiple testing were also reported using the Holm method [45] . 474
475
Mathematical model of reservoir depletion
476
We have used a mathematical model of the exponential clearance of the HIV reservoir on 477 consistent ART previously [28] . We extended that model to consider joint treatment with ARTand CRISPR gene therapy. Here, the reservoir was modeled as a multi-strain system. For each 479 strain, a clearance rate was chosen from the available data ranges [27] . We do not consider the impact of delivery, 494 which was previously described in [35] . 495
The model is simulated using a hybrid stochastic simulation algorithm [48] . When the 496 number of cells in a quasispecies is large ‫ܮ(‬ the simulation proceeds with a direct stochastic " Gillespie" algorithm [50] . 498 Table S1 . (A) Correlation between predicted activity and target site conservation (B) Correlation 678 between measured and predicted activity (C) Correlation between measured activity and target 679 site prevalence 680 681   Table S2 . List of highly conserved, subtype-specific triplet/paired gRNAs 682 683 Table S3 . GFP knockdown with candidate guides tested using fluorescent reporter 684 685 
